The estimated Net Worth of Anil Kapur is at least $1.85 Millón dollars as of 10 June 2024. Mr. Kapur owns over 421,875 units of Geron stock worth over $1,852,031 and over the last 5 years he sold GERN stock worth over $0. In addition, he makes $0 as Executive Vice President y Corporate Strategy and Chief Commercial Officer at Geron.
Anil has made over 1 trades of the Geron stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 421,875 units of GERN stock worth $447,188 on 10 June 2024.
The largest trade he's ever made was exercising 421,875 units of Geron stock on 10 June 2024 worth over $447,188. On average, Anil trades about 30,134 units every 0 days since 2019. As of 10 June 2024 he still owns at least 421,875 units of Geron stock.
You can see the complete history of Mr. Kapur stock trades at the bottom of the page.
Anil Kapur serves as Executive Vice President, Corporate Strategy and Chief Commercial Officer of the Company. Mr. Kapur has served as our Executive Vice President, Corporate Strategy and Chief Commercial Officer since December 2019. Prior to joining Geron, Mr. Kapur was Chief Commercial Officer at Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, from February 2018 to November 2019. From October 2016 until February 2018, Mr. Kapur was Vice President, Head of Early Assets, Biomarkers and External Innovation for Worldwide Oncology Commercialization at Bristol-Myers Squibb Company, a global biopharmaceutical company. Mr. Kapur served as Vice President, Global Head of Commercial and Portfolio Strategy at Baxalta, Incorporated, in a newly created Oncology Division, from November 2015 until after its acquisition by Shire plc in July 2016. Before joining Baxalta, Mr. Kapur held marketing and sales leadership roles of increasing responsibility during his 15-year tenure at the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). As Vice President, Commercial Leader, Hematology Franchise in Janssen’s Global Commercial Strategy Organization, he led the development and execution of commercial strategy and launch plans for in-market development, late development, and early pipeline assets, including imetelstat. Among Mr. Kapur’s most recognized achievements while at Janssen were the successful global launches of two transformational blockbuster hematology-oncology drugs, Imbruvica and Darzalex. Mr. Kapur holds a Bachelor of Engineering from Birla Institute of Technology in India; an M.S. in Industrial Engineering from Louisiana Tech University; and an M.B.A from the Fuqua School of Business at Duke University.
Anil Kapur is 50, he's been the Executive Vice President y Corporate Strategy and Chief Commercial Officer of Geron since 2019. There are 17 older and 3 younger executives at Geron. The oldest executive at Geron Corp. is Stephen N. Rosenfield, 71, who is the Exec. VP, Chief Legal Officer & Corp. Sec..
Anil's mailing address filed with the SEC is C/O VERASTEM, INC.,, 117 KENDRICK ST., SUITE 500, NEEDHAM, MA, 02494.
Over the last 21 years, insiders at Geron have traded over $2,393,273 worth of Geron stock and bought 340,678 units worth $567,384 . The most active insiders traders include John A Scarlett, Daniel Bradbury y Stephen Rosenfield. On average, Geron executives and independent directors trade stock every 93 days with the average trade being worth of $587,812. The most recent stock trade was executed by Andrew J Grethlein on 8 July 2024, trading 674,348 units of GERN stock currently worth $1,159,879.
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
Geron executives and other stock owners filed with the SEC include: